Table 3 Genotypic distribution and allele frequency of rs4910623, rs323085 and rs10158937 and association with VA response at six and three months of anti-VEGF treatment in the Melbourne discovery cohort.

From: GWAS study using DNA pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF treatment response in age-related macular degeneration

6 Month

SNP

A1

A2

Genotype frequency*

Allele frequency +

P-Value

OR 95% CI

Responders

Non-responders

Responders

Non-Responders

rs4910623

G

A

0.23/0.52/0.25

0.54/0.36/0.10

0.49/0.51

0.72/0.28

5.7 × 10 −5

2.58 (1.63–4.10)

rs323085

C

T

0.30/0.28/0.69

0/0.70/0.93

0.17/0.83

0.03/0.97

6.5 × 10−4

0.16 (0.06–0.46)

rs10158937

C

A

0.06/0.33/0.61

0/0.17/0.83

0.23/0.77

0.08/0.92

1.3 × 10−3

0.32 (0.17–0.65)

3 Month

rs4910623

G

A

0.25/0.51/0.24

0.52/0.37/0.11

0.51/0.49

0.71/0.29

1.5 × 10 −3

2.23 (1.36–3.66)

rs323085

C

T

0.02/0.25/0.73

0.02/0.22/0.76

0.14/0.86

0.13/0.87

0.81

0.92 (0.47–1.81)

rs10158937

C

A

0.06/0.33/0.62

0.02/0.13/0.85

0.22/0.78

0.09/0.91

9.0 × 10−3

0.36 (0.17–0.77)

  1. Definition of response was the same as in the pooled GWAS: Non-responders are patients who lost ≥5 ETDRS letters and the remainder were classified as responders P-Value: Calculated using logistic regression adjusted for baseline visual acuity, OR = odd ratio, representing trend per copy effect of risk or minor allele on VA outcome, highlighted in bold for each SNP, CI: Confidence Interval, *Genotype frequency A1A1/A1A2/A2A2, +Allele frequency A1/A2.
Back to article page